| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-09 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.23 | 5e-09 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.2 | 3e-08 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 8e-08 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.22 | 8e-08 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.2 | 8e-08 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.18 | 3e-07 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-07 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.19 | 7e-07 |